Efficient Ligand Passivation Enables Ultrastable CsPbX3 Perovskite Nanocrystals in Fully Alcohol Environments

Halide perovskite nanocrystals (PNCs) have demonstrated their wide potential to fabricate efficient optoelectronic devices and to prepare promising photocatalysts for solar-driven photo(electro)chemical reactions. However, their use in most of the practical applications is limited due to the instability of PNCs in polar environments. Here, the preparation of non-encapsulated CsPbX3 nanocrystals dispersed in fully alcohol environments, with outstanding stability through surface defect passivation strategy is reported. By using didodecyldimethylammonium bromide (DDAB) during material post-treatment, highly luminescent CsPbBr3 PNCs with remarkable stability in methanol/butanol medium up to 7 months with near-unity photoluminescence quantum yield are achieved. This approach is extrapolated to stabilize iodine-based CsPbBr3-xIx and CsPbI3 PNCs, showing an improvement of their photoluminescence features and stability in these high polar alcohols up to 6 h. DDAB mediates the defect suppression through ligand exchange and avoids the full permeation of alcohol to be in contact with the PNCs. In this context, DDAB induces ionization of alcohol molecules to strengthen the surface passivation. The findings open the door to the development of long-term stable CsPbX3 PNCs with high optical performance to be used in polar environments.This work was supported by the European Innovation Council (EIC) via OHPERA project (grant agreement 101071010), the Spanish Ministry of Science and Innovation under projects STABLE (PID2019-107314RB-I00) and ECOCAT (PID2020-116093RB-C41), the Spanish Ministry of Science and Innovation under project She-LED (PID2021-122960OA-I00), and the Generalitat Valenciana via Prometeo Grant Q-Solutions (CIPROM/2021/078). C.A.M. acknowledges APOSTD grant (APOSTD/2021/251) for funding. The authors also thank the Ministry of Education, Youth and Sports of the Czech Republic for the financial support of XPS measurements using CEMNAT infrastructure (project LM 2018103). The authors are very grateful to the “Serveis Centrals d'Instrumentació Científica (SCIC)” of the Universitat Jaume I

EFEITOS DE 16 SEMANAS DE TREINAMENTO AERÓBIO INTERVALADO PERIODIZADO SOBRE VALORES DE GLICEMIA EM INDIVÍDUOS COM SÍNDROME METABÓLICA

A Síndrome Metabólica (SM) é conhecida como um conjunto de fatores de risco (hipertensão, hiperglicemia, dislipidemia e obesidade abdominal), os quais estão associados ao desenvolvimento de diabetes melitus tipo II, doença cardiovascular e morte prematura. O objetivo foi analisar os efeitos de um Treinamento aeróbio intervalado (TAI) periodizado sobre níveis glicêmicos em indivíduos com SM. Participaram do estudo 20 pessoas, com idade entre 35 e 60 anos de ambos os sexos. Realizaram-se análises bioquímicas e antropométricas nos momentos pré e pós intervenção. Não houve diferença estatística significativa na comparação entre e intra grupos para a variável glicemia, peso e índice de massa corpórea (IMC). Embora recomenda-se a prática regular de exercício físico para o controle glicêmico, o TAI, sem controle alimentar, apresentou apenas manutenção da glicemia de jejum. Conclui-se que 13 semanas de TAI periodizado não foi capaz de modificar os níveis de glicemia de jejum em indivíduos com SM

Temas Socio-Jurídicos. Volumen 23 No. 49 Diciembre 2005

El texto que se ofrece a continuación se ha estructurado en función del estudio de dos momentos claves en la configuración del institucionalismo. En un primer momento se retoman las iniciales ideas de Veblen, Commons y Mitchell, buscando identificar en ellas el tópico que las conecta con el proceso de construcción de este marco analítico. En un segundo momento, se examina cómo la ideas de los protoinstitucionalistas mencionados, son retomadas por Coase, Williamson y North en tiempos y contextos relativamente lejanos a los que se plantearon los primeros enfoques, dándole forma a un enfoque analítico concebido para afianzar el rol de las organizaciones y promover la eficiencia en las transacciones sobre las que descansan el bienestar social, la transparencia política y el desarrollo económico.The text offered below has been structured based on the study of two key moments in the configuration of institutionalism. At first, the initial ideas of Veblen, Commons and Mitchell are taken up, seeking to identify in them the topic that connects them with the construction process of this analytical framework. In a second moment, it is examined how the ideas of the aforementioned proto-institutionalists are taken up by Coase, Williamson and North in times and contexts relatively distant from those of the first approaches, giving shape to an analytical approach designed to strengthen the role of organizations and promote efficiency in the transactions on which social welfare, political transparency rest and economic development

Levantamiento del velo corporativo. Panorama y perspectivas. El caso colombiano

Son múltiples y constantes los debates que se han dado en la comunidad jurídica nacional sobre permitir que los socios o accionistas de una sociedad respondan directamente con su patrimonio por las acreencias de la persona jurídica a través de la utilización de la "teoría del levantamiento del velo corporativo". Dada la importancia de este tema, expertos colombianos de primer nivel se reúnen en esta obra para exponer sus puntos de vista sobre la aplicación de esta institución en Colombia. Adicionalmente, este libro incluye el informe de ejecución del proyecto de investigación , adelantado por la línea de investigación en Derecho Comercial del Grupo de Derecho Privado de la Facultad de Jurisprudencia, el cual fue financiado por el Centro de Investigaciones, Estudios y Consultoría (CIEC) de la Universidad del Rosario.Dada la importancia de este tema, expertos colombianos de primer nivel se reúnen en esta obra para exponer sus puntos de vista sobre la aplicación de esta institución en Colombia

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p&lt;0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (&lt;1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (&lt;1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Colombian consensus recommendations for diagnosis, management and treatment of the infection by SARS-COV-2/ COVID-19 in health care facilities - Recommendations from expert´s group based and informed on evidence

La Asociación Colombiana de Infectología (ACIN) y el Instituto de Evaluación de Nuevas Tecnologías de la Salud (IETS) conformó un grupo de trabajo para desarrollar recomendaciones informadas y basadas en evidencia, por consenso de expertos para la atención, diagnóstico y manejo de casos de Covid 19. Estas guías son dirigidas al personal de salud y buscar dar recomendaciones en los ámbitos de la atención en salud de los casos de Covid-19, en el contexto nacional de Colombia

Discutindo a educação ambiental no cotidiano escolar: desenvolvimento de projetos na escola formação inicial e continuada de professores

A presente pesquisa buscou discutir como a Educação Ambiental (EA) vem sendo trabalhada, no Ensino Fundamental e como os docentes desta escola compreendem e vem inserindo a EA no cotidiano escolar., em uma escola estadual do município de Tangará da Serra/MT, Brasil. Para tanto, realizou-se entrevistas com os professores que fazem parte de um projeto interdisciplinar de EA na escola pesquisada. Verificou-se que o projeto da escola não vem conseguindo alcançar os objetivos propostos por: desconhecimento do mesmo, pelos professores; formação deficiente dos professores, não entendimento da EA como processo de ensino-aprendizagem, falta de recursos didáticos, planejamento inadequado das atividades. A partir dessa constatação, procurou-se debater a impossibilidade de tratar do tema fora do trabalho interdisciplinar, bem como, e principalmente, a importância de um estudo mais aprofundado de EA, vinculando teoria e prática, tanto na formação docente, como em projetos escolares, a fim de fugir do tradicional vínculo “EA e ecologia, lixo e horta”.Facultad de Humanidades y Ciencias de la Educació

Prevalence and management of musculoskeletal pain in rural communities

The general aim of this thesis was to investigate the prevalence and management of chronic musculoskeletal conditions, such as low back pain and knee pain, in rural and remote communities. This thesis included one systematic review with a meta-analysis of observational studies, reported in Chapter Two, that compared the prevalence of physical activity, physical inactivity, and sedentary behaviour in a population of rural and urban Australian adults. Twenty-eight studies reporting data on a total of 515,532 people were included and found that the prevalence of physical inactivity was higher in rural populations (prevalence difference 4%; 95% confidence interval [CI] = 0.4% to 8%), but the prevalence of physical activity was similar in both rural and urban populations (prevalence difference 1%; 95% CI = -3% to 5%). The implications of the study call to action to reduce the urban-rural inequality of different factors that are associated with physical inactivity, such as the promotion of current guidelines focused on leisure physical activity, and adequate infrastructure for the safe practice of sports and exercise. The systematic review reported in Chapter Three includes a meta-analysis of observational studies reporting on the worldwide prevalence of musculoskeletal conditions, such as back, knee, hip, and shoulder pain in rural compared to urban populations. The review included 42 studies from 24 countries with a total sample of 489,439 people, and the results indicated that hip (mean odds ratio [OR]=1.62; 95% CI=1.23 to 2.15), shoulder (OR=1.42; 95% CI=1.06 to 1.90), and overall musculoskeletal pain ([OR]=1.26, 95% [CI]= 1.08 to 1.47; n=302,911) were more prevalent in rural compared to urban populations. Similarly, although not statistically significant, back (OR=1.18, 95% CI=0.97 to 1.43; n=225,950), and knee pain (OR=1.13; 95% CI=0.83 to 1.52), but not neck pain (OR= 0.89; 95% CI=0.60 to 1.32), were more prevalent in rural compared to urban populations. Interestingly, the meta-analysis showed that adults in rural areas were less likely to seek treatment for musculoskeletal conditions than their urban counterparts (OR= 0.76; 95% CI=0.55 to 1.03). Lastly, a randomised controlled trial that included 156 participants was conducted and reported in Chapters Four and Five of this thesis. The trial aimed to assess the effectiveness of a physiotherapist delivered real-time eHealth intervention including a physical activity plan and a personalised resistance training program, compared with usual care on physical function in adults with chronic non-specific low back pain or knee osteoarthritis in rural Australia. The primary outcome of physical function was assessed with the Patient-Specific Functional Scale, which ranges from 0 to 30, with higher values indicating better levels of function. The secondary outcome of disability was assessed using the Roland-Morris Disability Questionnaire in participants with low back pain, which ranges from 0 to 24 with lower scores indicating lower disability, or with the Western Ontario and McMaster Osteoarthritis Index in participants with knee osteoarthritis, which ranges from 0 to 68 (function section) with lower scores indicating lower disability. Health-related quality of life was measured using the Assessment of Quality of Life 8D instrument, which ranges from 0 to 100, with higher scores indicating better quality of life. The findings reported in Chapter Five showed that the eHealth intervention provided greater clinically significant benefits in physical function at three months (mean between-group difference 3.63; 95% CI= 1.31 to 5.94), and at six months (mean between-group difference: 3.59; 95%CI= 1.14 to 6.05) compared to usual care. Disability (mean between-group difference 7.26; 95%CI= 2.14 to 12.38), and quality of life (mean between-group difference 4.51; 95%CI= 0.01 to 9.01) were statistically significantly higher in the eHealth intervention group at the three-month follow-up. No other between-group differences were found for the remaining outcomes or follow-ups. Results of this study showed that an eHealth intervention is effective to improve physical function, and can potentially complement and enhance face-to-face consultations, for people suffering from musculoskeletal pain in rural communities. These findings are important to inform rural and primary healthcare policy and clinical practice in Australia